GPER1 and breast cancer: Interestingly, low expression of cytoplasmic GPER was significantly associated with adverse survival of patients who received endocrine therapy (P=0.003) (Figure 4B); whereas no association was observed in breast cancer-specific survival in patients who did not receive endocrine therapy (P=0.205) (Figure 4A).